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Abstract
New treatments for hepatitis C virus (HCV) may be highly effective but are associated with 
substantial costs that may compel clinicians and patients to consider delaying treatment. This 
study investigated the cost-effectiveness of these treatments with a focus on patients in early stages 
of liver disease. We developed a state-transition (or Markov) model to calculate costs incurred and 
quality-adjusted life-years (QALYs) gained following HCV treatment, and we computed 
incremental cost-effectiveness ratios (cost per QALY gained, in 2012 US dollars) for treatment at 
different stages of liver disease versus delaying treatment until the subsequent liver disease stage. 
Our analysis did not include the potential treatment benefits associated with reduced non–liver-
related mortality or preventing HCV transmission. All parameter values, particularly treatment 
cost, were varied in sensitivity analyses. The base case scenario represented a 55-year-old patient 
with genotype 1 HCV infection with a treatment cost of $100,000 and treatment effectiveness of 
90%. In this scenario, for a 55-year-old patient with moderate liver fibrosis (Metavir stage F2), the 
cost-effectiveness of immediately initiating treatment at F2 (versus delaying treatment until F3) 
was $37,300/QALY. For patients immediately treated at F0 (versus delaying treatment until F1), 
the threshold of treatment costs that yielded $50,000/QALY and $100,000/QALY cost-
effectiveness ratios were $22,200 and $42,400, respectively.
Conclusion—Immediate treatment of HCV-infected patients with moderate and advanced 
fibrosis appears to be cost-effective, and immediate treatment of patients with minimal or no 
fibrosis can be cost-effective as well, particularly when lower treatment costs are assumed.
In the United States, hepatitis C virus (HCV) infection imposes a considerable burden of 
morbidity, mortality, and health care costs.1–4 An estimated 50% of US HCV infections 
remain undiagnosed,5–7 and of the total infected population as few as 38% of patients were 
referred to care.5 Among a sample of US veterans, only 12% of HCV-infected patients had 
initiated treatment.8 While the most recent guidelines recommend treatment for nearly all 
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patients with chronic HCV infection, they recommend more “urgent initiation” of treatment 
among patients with advanced fibrosis or cirrhosis.9 In particular, patients with severe 
fibrosis (Metavir stage F3) and compensated cirrhosis (F4) are characterized as having the 
“highest” treatment priority and patients with moderate fibrosis (F2) are characterized as 
having “high” treatment priority.9 Liver fibrosis is a measure of apparent liver damage done 
by inflammation; the Metavir liver fibrosis scale ranges from F0 (no liver damage) to F4 
(compensated cirrhosis). The key contribution of our study is to address these treatment 
guidelines by examining the decision to initiate treatment immediately or delay treatment 
until a patient progresses to a later stage of liver disease.
Effective and expensive treatment regimens present a challenge to payers and other 
stakeholders who must consider the costs and health benefits of HCV screening and 
treatment strategies. This study develops a cost-effectiveness model and utilizes disease-
related and economically related parameters from published sources as well as from data 
obtained in the longitudinal Chronic Hepatitis Cohort Study (CHeCS).10 We calculated the 
costs and effects in quality-adjusted life-years (QALYs) gained following initiation of HCV 
treatment based on fibrosis level. We modeled treatment as a generic regimen of highly 
effective antivirals with a base case cost of $100,000 per patient. In sensitivity analyses we 
varied our assumptions about treatment cost, age, stage of liver fibrosis, and other 
parameters. Broadly, our objectives were to gain a better understanding of the relationships 
between treatment costs, cost-effectiveness, and stages of liver disease, as opposed to 
estimating the cost-effectiveness of a particular medical or pharmaceutical product. 
Consideration of treatment at early stages of liver disease is relevant to many of the 
approximately 3 million individuals who are infected with HCV.5 In a study of four large US 
medical centers, the majority of biopsied patients (62%) exhibited early stages of liver 
disease with fibrosis levels of F2, F1, or F0.11
Materials and Methods
Analytic Overview
We developed a cost-effectiveness model to represent the clinical experience of a diagnosed, 
chronically infected HCV patient (Fig. 1). Consistent with other studies,12–15 the model 
classifies patients according to treatment status and liver disease stage. The investigation 
compares a relatively constrained treatment strategy (treatment at fibrosis stages F3 and F4) 
to more expansive treatment strategies where treatment is initiated at earlier stages of liver 
disease (fibrosis stages F2, F1, or F0). The patient incurs medical costs and accrues QALYs 
annually. For a given treatment strategy, patients are treated only if their liver disease stage is 
at or beyond the fibrosis stage associated with the given strategy.
Because all data were obtained from secondary sources without patient-level information, 
this study was exempt from human subjects review and approval.
Model Details
We used Microsoft Excel to construct the model. We modeled a closed population of adults 
who had become chronically infected with HCV prior to the start of the analysis. There was 
Leidner et al. Page 2
Hepatology. Author manuscript; available in PMC 2018 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
no entry into the population over time, and exit was possible due to death from HCV 
infection or from other (non-HCV) causes. We used annual time steps such that each year a 
patient could transition from one state to another or remain in his or her current state, 
according to the transition probabilities in Table 1. The time horizon of the analysis was the 
lifetime of the modeled population. We used a societal perspective. All future outcomes, 
including costs and QALYs, were discounted at 3% annually. All costs were adjusted to 
2012 US dollars.
Treatment Status—The model contains population compartments to account for 
treatment status. Initially, patients are assumed to be treatment-naive. Patients may be treated 
a second time if their first treatment is unsuccessful. Population compartments include the 
following: diagnosed, first treatment, failed first treatment, second treatment, failed second 
treatment, recovered, and three compartments to represent end-stage liver disease (ESLD) 
(Fig. 1). The ESLD compartments are decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC), and liver transplant (LT). Recovered patients are HCV-uninfected because 
they achieved a sustained virologic response following treatment.
Natural History—The staging of liver disease follows the Metavir scale, where F0 
represents mild liver disease (or no liver fibrosis) and F4 represents severe liver disease 
(compensated cirrhosis). Patients in the diagnosed and the failed treatment compartments are 
subject to the progression of liver disease. Following successful treatment, patients do not 
progress to higher noncirrhotic liver disease stages. Patients who are cirrhotic (F4) are at risk 
of developing ESLD (either DC or HCC), but HCV-uninfected patients are at a lower risk 
than HCV-infected patients (Table 1).
Cost-Effectiveness—Cost-effectiveness ratios compared the costs and health outcomes 
of two treatment scenarios. The treatment strategies we examined included treatment at F2, 
at F1, and at F0. The “treatment at F2” strategy initiates treatment if patients have a fibrosis 
level of F2 or higher. The treatment strategies are increasingly expansive, such that the 
“treatment at F1” strategy initiates treatment if patients have a fibrosis level of F1 or higher 
and the “treatment at F0” strategy initiates treatment if patients have a fibrosis level of F0 or 
higher. We calculated the cost-effectiveness associated with the health care decision to either 
initiate treatment immediately or delay treatment until a subsequent fibrosis stage (i.e., the 
cost-effectiveness ratio compares a given treatment strategy with the next least expansive 
strategy).
Inputs
Liver Disease Progression—Disease progression occurs among precirrhotic liver 
disease stages (F0–F3) as well as from cirrhosis (F4) to ESLD sequelae (i.e., DC and HCC). 
Precirrhotic progression rates are applied only to HCV-infected patients who are not in 
treatment, such that no precirrhotic progression of liver disease occurs among recovered 
(HCV-uninfected) patients or for the year a patient is in treatment. We chose to use 
progression rates estimated from CHeCS data as the base case progression rates because the 
CHeCS provides a large sample of patients that captures the aging US HCV-infected 
population of greatest interest to this study. Specifically, we applied a stage-specific 
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estimation procedure16 to biopsy records from CHeCS patients who were not coinfected 
with hepatitis B virus or human immunodeficiency virus and had no other known major 
comorbidities. This stage-specific procedure yielded separate rates for the transition from F0 
to F1, F1 to F2, and so on. The CHeCS-based rates were consistent with other published 
fibrosis progression rates, well within the upper and lower ranges of those studies16,17 (Table 
1). The fibrosis progression rates used in sensitivity analyses were obtained from previously 
published studies.1,17 For an HCV-infected patient with cirrhosis, the annual probabilities of 
developing HCC and DC in the base case scenario were assumed to be 1.9% and 4.6%, 
respectively. These values were based on sources in the literature13,15 and conformed with 
preliminary analysis of CHeCS data. Relative to HCV-infected patients, HCV-uninfected 
patients have a 76.4% lower probability of developing HCC18 and 91.3% lower probability 
of developing DC.19 As with fibrosis progression rates, the range of ESLD-related transition 
probabilities used in sensitivity analyses were obtained from previously published studies.13
Treatment Effectiveness and Costs—Treatment regimens of direct-acting antivirals 
that do not burden patients with the adverse events associated with the injection of pegylated 
interferon have been approved by the US Food and Drug Administration, with more 
regimens likely to be approved in the future.20 Preliminary evidence suggests success rates 
greater than 90% for these treatments, even for the more difficult-to-treat genotype 1 
patients.21–24 We assumed a base case probability of treatment success of 90% (Table 1).
Since these treatments are relatively new, patient-based, real-world costs are not precisely 
known. With even more new treatments likely to enter the market in the coming years, the 
future cost of treatment for HCV infection is difficult to predict. Therefore, we chose to 
assess the cost-effectiveness of a generic “treatment” at a baseline cost of $100,000 per 
patient per course, which could conceivably represent any number of emerging 
pharmaceuticals (or combinations thereof) in addition to any other treatment-associated 
costs, such as laboratory expenses and outpatient visits. To accommodate the state of 
substantial uncertainty regarding the current and future costs of HCV treatments, the base 
case assumption of $100,000 treatment cost was varied extensively in multiple sensitivity 
analyses.
Chronic Liver Disease Costs and QALYs—As liver fibrosis progresses, health care 
costs increase because of greater frequency of monitoring and screening as well as greater 
frequency and costs associated with hospital visits.25 Patients in advanced stages of liver 
fibrosis also experience a reduction in their quality of life. Accordingly, parameter values for 
both health care costs and quality of life change dramatically as the patient enters cirrhosis 
(F4) (Table 1).
Infection with HCV, irrespective of fibrosis level, may impose physical and psychological 
effects on a patient. For this reason, HCV-infected patients are subjected to a QALY 
multiplier of 0.98 (Table 1) in the base case, which reduces quality of life of HCV-infected 
patients by 2% relative to HCV-uninfected persons. This assumption is consistent with 
previously published cost-effectiveness studies13,26,27 as well as previous studies that 
measure health-related quality of life.28–30 Even though some studies have found negligible 
quality-of-life reductions associated with HCV-infected patients when the HCV infection 
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status is unknown to them,31 our model only considers patients who have been diagnosed. 
Studies have documented the harmful effects of HCV infection on a patient’s psychological 
well-being32 as well as reductions in health-related quality-of-life measurements following a 
positive diagnosis.33 Furthermore, a portion of the reduction in quality of life from HCV 
infection has been documented to rebound, or recover, following successful treatment and a 
sustained virologic response.34
ESLD Costs and QALYs—Relative to cirrhosis, patients in ESLD incur even greater 
medical costs and experience lower quality of life. Patients in either DC or HCC may receive 
LT. All three ESLD states (DC, HCC, and LT) are subdivided into first-year and subsequent-
year compartments to allow for different medical costs and disease-related death rates across 
the years of ESLD (Table 1).
Sensitivity Analyses
Base case model results focus on a 55-year-old HCV-infected patient with a treatment cost 
of $100,000. In our sensitivity analyses, we vary a wide range of assumptions. Specifically, 
we performed one-way and multiway sensitivity analyses in which one or more parameter 
values (or sets of parameter values, such as liver disease stage transitions) were varied at a 
time, holding all other parameters at their base case values. We conducted a threshold 
analysis on the treatment cost parameter to estimate the specific treatment cost that yielded 
cost-effectiveness ratios of $50,000/QALY and $100,000/QALY for patients with no fibrosis 
(F0). We also computed treatment cost thresholds for several policy-relevant cost-
effectiveness levels, stratified by patients who are diagnosed at different fibrosis levels.
Results
Base Case Results
The base case model scenario found that the treatment of patients diagnosed at F2 was 
generally cost-effective, exhibiting an incremental cost-effectiveness ratio (ICER) of 
$37,300/QALY (compared to diagnosis at F2 and treatment at F3) (Table 2). At earlier 
stages of liver disease, the ICER increased to $174,100/QALY and $242,900/QALY, 
respectively, for patients diagnosed and treated at F1 (compared to being diagnosed at F1 
and treated F2) and diagnosed and treated at F0 (compared to being diagnosed at F0 and 
treated at F2) (Table 2). The treatment of patients who are diagnosed and treated at F0 was 
compared to that of patients who are diagnosed at F0 and treated at F2 because, for patients 
diagnosed at F0, treatment at F1 was weakly dominated by treatment at F0.
Sensitivity Analysis
Table 3 reports the ICERs while varying a variety of parameter groups, using the low and 
high parameter values presented in Table 1. In one-way sensitivity analyses for patients with 
F2 fibrosis, ICERs range from being cost-saving (<$0/QALY) when nontreatment medical 
costs are assumed to be high to being as much as $112,300/QALY when liver disease stage 
transitions are assumed to be low. As expected, the ICERs varied more substantially in the 
multiway sensitivity analyses. For example, if an HCV patient has liver fibrosis of F1, then 
treating that patient immediately (treated at F1 compared to treated at F2) generates an ICER 
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that ranges between $16,500/QALY and $665,200/QALY when varying only one parameter 
at a time and between being cost-saving (<$0/QALY) and $1,807,500/QALY when varying 
all economic parameters simultaneously (Table 3). Additional multiway sensitivity analyses 
were also conducted (see Supporting Information).
Results from threshold analyses are presented in Fig. 2 and Table 4. For patients with 
moderate fibrosis (F2), the treatment costs of $14,900, $128,800, and $242,800 yielded, 
respectively, cost-effectiveness ratios of $0 (or cost saving), $50,000, and $100,000 per 
QALY gained (Table 4). When we assumed the patient had no evidence of fibrosis (F0), the 
cost-saving threshold of treatment cost was $2,000 (Table 4). When the cost-effectiveness 
thresholds were increased to $50,000 and $100,000, the resulting threshold treatment costs 
for patients with no evidence of fibrosis (F0) increased, respectively, to $22,200 and $42,400 
(Table 4).
Discussion
This analysis investigates a common clinical situation, in which the clinician and patient 
must choose between starting treatment of HCV infection immediately or delaying treatment 
until later. In the base case scenarios—a 55-year-old patient, treatment cost of $100,000, and 
treatment effectiveness of 90%—immediate (versus delayed) treatment of a patient with 
fibrosis level of F0, F1, and F2 was associated with cost-effectiveness ratios, respectively, of 
$242,900, $174,100, and $37,300 per QALY gained. Earlier initiation of treatment was more 
cost-effective under scenarios of higher disease progression rates, when quality-of-life 
assumptions favored treatment, when treatments were more effective, and when lower 
treatment costs were assumed. We also found that for patients diagnosed and treated at F0, 
the treatment cost thresholds that yielded $50,000/QALY and $100,000/QALY cost-
effectiveness ratios were $22,200 and $42,400, respectively.
Sensitivity analyses showed that results responded to changes in the baseline assumptions 
about parameter values. In particular, varying the assumption on the impact of a successful 
treatment on the quality of life for an HCV-infected patient produced relatively large 
changes in cost-effectiveness and the treatment cost thresholds. This finding highlights the 
amount of variation that exists given different assumptions about the effect of HCV on a 
patient’s quality of life in early and late stages of liver disease and underscores a need to 
better understand the morbidity burden of HCV in both early and late stages of liver disease.
Although we know of no other study that has assessed the cost-effectiveness of HCV 
treatment considering the stage-specific treatment decision for all the early stages of liver 
disease, at least two recent cost-effectiveness studies have also investigated the issue of 
timing of HCV treatment. Younossi et al. 35 found that treating all patients with an all-oral 
treatment regimen yielded an ICER of $15,700 when compared to treating only patients with 
F2–F4 fibrosis with an all-oral regimen. Their base case assumptions were more favorable 
toward a “treat all” strategy than those used in this study. Of particular relevance was that 
they assumed the difference between the quality of life for an HCV-infected and an HCV-
uninfected patient was 10% (or their QALY multiplier for HCV infection was 0.90). Our 
base case quality-of-life assumptions were more conservative. We reduced quality of life for 
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HCV-infected patients by 2% (or used a QALY multiplier of 0.98), the rationale for which 
we discuss more extensively in the Supporting Information. Deuffic-Burban et al.36 
investigated the decision to treat a patient immediately with interferon-based regimens or to 
delay treatment until all-oral regimens become available, and they found that delaying 
treatment was cost-effective for all patients except for those who had already developed 
cirrhosis. While their analyses differed in that they assumed all-oral regimens were not 
immediately available, we believe their conclusions were in accordance with ours: delaying 
treatment for patients who have little evidence of liver damage can be cost-effective if 
treatment costs are sufficiently high or if disease progression is sufficiently slow, among 
other factors.
Our results are also generally consistent with other recent assessments of the cost-
effectiveness of HCV treatments.3,14,37,38 For example, the incremental cost-effectiveness of 
triple therapy using direct-acting antivirals (compared to dual therapy) was between $29,200 
and $88,900 per QALY.37 Another recent study found the cost-effectiveness of triple therapy 
(compared to dual therapy) to be between $62,900 and $102,600 per QALY among mildly 
fibrotic patients and between $32,800 and $54,100 per QALY among patients with advanced 
fibrosis.38 In similar fashion (without regard to the cost-effectiveness at each fibrosis stage), 
Hagan et al.14 found that all-oral therapy cost-effectiveness was $44,500/QALY (compared 
to conventional therapy, which was dual therapy for genotypes 2 and 3 and triple therapy for 
genotype 1). These studies14,37,38 evaluated different therapy types (comparing all-oral 
therapy to triple therapy or comparing triple therapy to dual therapy) while assuming a given 
set of fibrosis levels, whereas our study focused on liver disease stage–specific treatment.
Strategies for HCV testing and linkage to care have been found to be cost-effective in 
reducing HCV morbidity and mortality.39–42 New therapeutic agents can increase the health 
benefits associated with these strategies. However, payers and other stakeholders are 
concerned about their cost and are therefore evaluating these expenditures against the health 
benefits achieved with these agents. The potential expenditures for HCV screening and 
treatment strategies are not trivial, given that the United States has approximately 3 
million43 HCV-infected persons. Results from our model indicate that HCV therapy appears 
to be cost-effective for HCV-infected persons with evidence of moderate liver disease.
The findings should be interpreted in light of the limitations of our study. We assumed that 
HCV-related deaths only occurred as a consequence of developing ESLD, while substantial 
non–liver-related mortality may be associated with HCV.44 Furthermore, our model does not 
account for comorbid conditions such as vasculitis and diabetes mellitus, which can be made 
less severe and life-threatening following successful treatment of HCV infection. The 
inclusion of these conditions in the model would increase the benefit received from 
treatment and thereby make the incremental cost-effectiveness ratios associated with 
treatment more attractive and raise the corresponding treatment cost thresholds. While some 
studies focusing on injection drug users have found evidence that treatment is a cost-
effective intervention to prevent future transmissions,45 we assume no such benefits 
occurred after successful treatment. Although alcohol consumption was not explicitly 
accounted for in our modeling of liver fibrosis progression, using the fibrosis progression 
rates estimated from the CHeCS, due to the CHeCS cohort size and heterogeneity in terms 
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of racial, geographic, and economic characteristics, a mixture of alcohol consumption 
behaviors are likely represented. Considering these limitations, we provided ranges on all 
parameters and designed broad sensitivity analyses to capture scenarios that both favored 
and disfavored treatment cost-effectiveness. A literal interpretation of the model supposes 
that fibrosis status among HCV-infected patients is known with a high level of sensitivity 
and specificity, when in fact neither noninvasive methods nor biopsies can ascertain a liver’s 
fibrotic status with perfect accuracy; additionally, subjecting a patient to repeated liver 
biopsies to evaluate liver histology could evoke ethical concerns. Similarly, we also assumed 
that delayed treatment is a viable option for all patients at F0, F1, and F2. The cost-
effectiveness of immediate treatment is more favorable if delayed treatment is not an option 
(see Supporting Information).
In summary, treatment of HCV patients diagnosed with moderate to severe liver disease 
(F2–F4) was found to be cost-effective. Earlier treatment can be a cost-effective use of 
resources in some scenarios and with certain thresholds of treatment costs. In the current era 
of evolving antiviral therapy for HCV infection, these results can help to inform policies that 
guide initiation of therapy.
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Fig. 1. 
Population compartments and liver disease stages in the hepatitis C cost-effectiveness 
model. The curved arrows exiting ESLD states represent disease-induced mortality rates. 
Not pictured is that all patients are subject to age-adjusted natural mortality rates (see 
Supporting Information). “Diagnosed” indicates patients who have been diagnosed with 
HCV but have not initiated therapy; “First Treatment” indicates patients who are in therapy 
for HCV for the first time; “Failed First Treatment” indicates patients whose first HCV 
therapy was not successful and have yet to initiate their second therapy; “Second Treatment” 
indicates patients who are in therapy for HCV for the second time; “Failed Second 
Treatment” indicates patients whose first and second HCV therapies were not successful; 
“Recovered” indicates patients who have recovered from HCV following a successful 
therapy and are now HCV-uninfected; “ESLD” indicates states that represent end-stage liver 
disease, which include the first (year 1) and subsequent (year 2+) years of decompensated 
cirrhosis, hepatocellular carcinoma, and liver transplant.
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Fig. 2. 
Threshold analyses on treatment cost for HCV-infected patients with no fibrosis where each 
panel demonstrates the range of parameter values for (A) treatment effectiveness, (B) age of 
patient, (C) fibrosis progression rates, and (D) quality-of-life assumptions. The lines 
represent the incremental cost-effectiveness ratios for the treatment of hepatitis C–infected 
patients at liver disease stage F0 under various assumptions about parameter values. 
Treatment at F0 is compared to treatment F2 because treatment at F1 is dominated by 
treatment at F0 for the following scenarios: base case, high treatment effectiveness, age is 
70, low fibrosis progression rate, quality-of-life assumptions favorable for treatment. 
Abbreviations: FPR, fibrosis progression rate; QOL, quality of life.
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Table 3
Results of One-Way and Multiway Sensitivity Analyses*
Parameter Group Varied Scenario
Incremental Cost-Effectiveness Ratios ($/QALY)
Patient With F0, Tx at F0 
Versus F1
Patient With F1, Tx at F1 
Versus F2
Patient With F2, Tx at F2 
Versus F3
None Base case 242,900‡ 174,100 37,300
Epidemiological parameters
 Liver disease stage transitions Low 288,100‡ 251,100 112,300
High† 196,100 133,700 26,400
 Treatment effectiveness Low 438,400 292,300 62,700
High† 219,900‡ 160,800 34,700
 ESLD transitions Low 246,300‡ 181,700 42,900
High† 234,400 127,900 16,600
 Disease-induced deaths Low 243,900‡ 176,100 37,500
High† 242,100‡ 172,800 37,100
Health economic parameters
 Nontreatment medical costs Low 240,300‡ 172,700 39,500
High† 194,500 122,800 Cost saving
 ESLD medical costs Low 243,000‡ 174,600 38,900
High† 242,500‡ 173,300 34,900
 Treatment costs Low† 118,900‡ 84,300 15,400
High 366,800‡ 263,900 59,300
 Quality-of-life assumptions§ Favor Tx 19,000‡ 16,500 11,000
Disfavor Tx 10,860,800 665,200 46,300
 Discount rate Low† 111,500‡ 54,100 3900
High 343,800 266,200 70,100
All epidemiologic parameters Favor Tx 158,700 79,600 11,000
Disfavor Tx 527,400‡ 457,900 207,300
All economic parameters Favor Tx 300‡ Cost saving Cost saving
Disfavor Tx 28,967,600 1,807,500 144,200
All parameters Favor Tx Cost saving Cost saving Cost saving
Disfavor Tx 522,789,800 22,539,000 1,042,200
*
This table presents the incremental cost-effectiveness ratios comparing two scenarios under a variety of parameter assumptions. For example, the 
first value in the row labeled “Liver disease stage transitions/Low” is $288,100, which states that the incremental cost per QALY attained (the 
incremental cost-effectiveness ratio) for a patient with a starting fibrosis level of F0 is $288,100 when comparing initiating treatment at F0 versus 
initiating treatment at F1 (i.e., Tx at F0 versus F1). Sensitivity analyses are organized by parameter group, assuming a 55-year-old hepatitis C 
patient, with treatment of hepatitis C characterized by a generalized all-oral, direct-acting antiviral. When a parameter group was varied, all values 
in that parameter group were varied simultaneously. For example, in the “Low” scenario for “Liver disease stage transitions,” all values for the 
“Annual probability of a liver disease stage transition” in Table 1 were set to their low values. Similarly, in the “High” scenario for “treatment 
effectiveness,” all values for the “Probability of a successful treatment” in Table 1 were set to their high values. The “ESLD transitions” parameter 
group refers to all values for the “Annual probability of developing ESLD for HCV-infected patients” and “Annual probability of developing ESLD 
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for HCV-infected patients” as listed in Table 1. The “Disease-induced deaths” group refers to all values for the “Annual probability of liver-related 
death while in a given ESLD compartment” in Table 1. Cost and QALY parameters were varied by group as well. All costs are in 2012 US dollars. 
To simplify presentation, all numbers were rounded to the nearest hundred.
†
Indicates this scenario is included in the “favorable” scenarios where multiple parameter groups are varied simultaneously (i.e., “All 
epidemiologic parameters,” “All economic parameters,” and “All parameters”).
‡
In these scenarios, treatment at F1 is dominated by treatment at F0, so the ICERs presented compare treatment at F0 with treatment at F2.
§Within the “Quality-of-life assumptions” scenarios, the favorable scenario uses the high values for QALY (Table 1) associated with being HCV-
uninfected and the low value for the QALY multiplier (Table 1), thereby maximizing the difference between quality of life among infected and 
uninfected populations.
Abbreviation: Tx, treatment.
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Table 4
Hepatitis C Treatment Costs That Yielded Cost-Effectiveness Thresholds Stratified by Fibrosis Level*
Treatment Scenario
How Is Cost-Effectiveness Defined?
$0/QALY† $50,000/QALY $100,000/QALY
What treatment cost makes treatment cost-effective for patients regardless of stage?‡ 2000 22,200 42,400
What treatment cost makes treatment cost-effective for patients with a fibrosis level of F2 
or more severe?
14,900 128,800 242,800
What treatment cost makes treatment cost-effective for patients with a fibrosis level of F3 
or more severe?
84,200 713,600 1,343,000
*All costs are presented as 2012 US dollars using a 3% annual discount rate on future costs and benefits. Treatment effectiveness was assumed to 
be 90%, and patients were assumed to be 55 years old.
†A cost-effectiveness ratio equal to $0/QALY is commonly used to characterize “cost-saving” interventions.
‡
In this scenario, we computed the threshold treatment cost from the scenario characterized by immediate treatment of a patient at F0 versus 
delayed treatment at F2 (treatment at F0 dominates treatment at F1).
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